(Updated, 5:40 p.m.)
Ximedica announced Tuesday it has purchased the San Francisco-based Bridge Design, providing the Rhode Island-based medical technology development company with a West Coast hub.
The first two patients in IlluminOss Medical Inc.’s U.S. Lightfix clinical trial for the treatment of impending and pathologic fractures have been successfully treated at the Marshall University Joan C. Edwards School of Medicine.
(Updated 3:50 and 4:49 p.m.)
ProMetic Life Sciences Inc. has entered into a partnership with biotechnology company ProThera Biologics Inc. to develop and commercialize human plasma-derived inter-alpha inhibitor proteins to treat orphan diseases, which are rare diseases affecting fewer than 200,000 people.
An independent analysis of promising economic clusters for Providence to nurture has identified five stars: life sciences, food processing and packaging, social enterprise, design coupled with advanced manufacturing, and education technology.